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ABSTRACT 
 
   
 The purpose of this project is to investigate the various forms of stem cells, how they are 
used, the ethics in doing this research, and current and past laws regulating this research. The 
first chapter will describe the types of stem cells and their potencies, while the second will 
discuss potential treatments for example diseases. The third chapter will investigate the ethics 
and religious views on stem cell research. Then the final chapter will go over the legalities of 
stem cell research in the US on both the federal and state level, as well as in other countries. 
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PROJECT OBJECTIVES 
 
 
 The objective of this IQP is to examine the controversial topic of stem cells, focusing on 
both the technology itself and its ethical controversies.  Chapter-1 describes the various types of 
stem cells, showing their origins and potencies.  Chapter-2 documents example uses of this 
technology for several chosen diseases, carefully distinguishing pre-clinical animal experiments 
from human clinical trials.  Chapter-3 examines the ethics surrounding this controversial topic, 
while Chapter-4 examines the U.S. and international laws governing stem cell use.  Finally, a 
conclusion is made by the authors regarding the use of stem cells, and which laws best represent 
the authors’ points of view. 
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Chapter-1:  Stem Cell Types 
Brandon Alspach 
 
Throughout history, man has worked tirelessly on medical technology. Thousands of 
years ago, a medicine man would carve a hole in your skull to heal ailments; now we visit a drug 
store to treat the same ailment. But as much as we know about the human body and how to cure 
disease, there is still a great deal we do not know, and research seeks to find more cures. One 
such topic of strong current interest is stem cells. With this controversial topic, often people 
argue against their use before knowing all the facts. Perhaps before jumping to conclusions about 
stem cells and its research, we should ask more questions about them.  Are all stem cells the 
same? Do they all come from the same place in the human body and perform the same tasks? 
The answer to both those questions is no.  The purpose of this chapter is to describe the types of 
stem cells and their origins, focusing on which types destroy embryos. 
 
Stem Cell Potencies 
First discovered in 1908 by Russian histologist Alexander Maksimov, stem cell research 
did not expand much until the 1960’s, when it was discovered that self-renewing cells with blood 
forming characteristics existed in the bone marrow of mice (Till, 1961; Who Discovered…2012). 
The discovery of stem cells was monumental, as it was learned that they were very different 
from most cells in the body.  Two very important characteristics set them apart from other cells. 
First, stem cells are unspecialized and, as stated above, are “capable of renewing themselves 
through cell division” (Kirschstein and Skirboll, 2001). Second, the cells have the ability to 
differentiate into specific tissue types, determined by the cell’s potency, which varies from 
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totipotent, to pluripotent, multipotent, and unipotent. The prefix “toti”, meaning “wholly”, refers 
to cells fertilized in the past 1-3 days that have the ability to create an entire organism and its 
surrounding tissues. Totipotent cells have the ability to become a viable embryo. Newly 
fertilized zygotes through the 8-cell stage are totipotent. 
A pluripotent stem cell, with the prefix “pluri” meaning “several,” has the ability to 
become any of the 200 different types of cells found in the human body.  These cells are found in 
the inner cell mass of a 5-day old blastocyst. Embryonic stem (ES) cells are considered 
pluripotent, and their isolation from the blastocyst usually destroys the embryo; so ES cells are 
the most ethically controversial type of stem cell.  Multipotent stem cells, multi- meaning many 
or more than one, have a limited number of cells they can become, but do retain the ability to 
turn into cell types of  related cells. Examples of multipotent stem cells include hematopoietic 
stem cells (HSCs) and mesenchymal stem cells (MSCs).  HSCs taken from bone marrow and 
umbilical cord blood are among the best characterized of all the stem cell types, and have already 
shown successful therapeutic results. The final type of potency, unipotent stem cells, as their 
prefix suggests, are only capable of turning into a specific kind of cell, typically cells from the 
same tissue it resides (Types of Stem…2004).  The issue of stem cell potency is still hotly 
debated today, especially with iPS cells, which will be discussed below, and whether they are 
truly pluripotent. 
 
Embryonic Stem Cells 
Most often when referring to stem cells, it is jumped to the conclusion that the cells come 
from a human embryo, and that all stem cells are controversial. While it is true that some types 
come from embryos, the vast majority come from elsewhere. Stem cells can be categorized by 
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their location.  There are four main types of stem cells, embryonic stem cells, induced 
pluripotent stem cells, parthenogenetic embryonic stem cells, and adult stem cells, each of which 
will be discussed in detail.  
Embryonic stem (ES) cells are pluripotent stem cells taken from the inner cell mass of a 
blastocyst embryo (Figure-1).  Human ES cells were first isolated and grown in 1998 by James 
Thompson at the University of Wisconsin-Madison (Thomson et al., 1998).  Thomson showed 
that ES cells could be “sustained indefinitely in the lab” (Why Files…1998) by creating an ES 
cell line from which an endless supply of cells can be created.  Egg and sperm are united in vitro, 
and the zygote is grown about 5 days to the 100 cell blastocyst stage from which the ES cells are 
obtained, destroying the embryo.  No human implantation of the embryo is involved for 
blastocysts used for research.  Currently in the U.S., human embryos cannot be created solely for 
research purposes, but must come from reproductive clinics from the surplus supply left over 
from IVF procedures.    
 
 
 
 
 
 
 
Figure-1: Diagram of a Blastocyst Embryo.  The 
diagram shows the inner cell mass (green) from which 
embryonic stem cells are removed (Blastocyst English 
2007). 
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The initial protocol for growing ES cells required a feeder layer of mouse fibroblast cells, 
which provided a scaffold and growth factors.  But due to worries about mixing animal and 
human cells for therapy experiments, subsequent protocols use non-cellular extracellular matrix 
scaffolds (Klimanskaya et al., 2005).  Not every dish yields a cell line.  In some cases, the cells 
differentiate into other cells, or they begin to show genetic abnormalities. To create an 
embryonic stem cell line, over the course of months the cells must be re-plated in a cycle called 
subculture, with each cycle called a passage. At any point during this process, the cells can be 
frozen and kept for indefinite amounts of time, then thawed and re-plated.  
To ensure that the culture remains as embryonic stem cells, scientists periodically test the 
cells to ensure they remain undifferentiated, however the scientific community has not been able 
to agree on a standard method of determining whether the cells are undifferentiated.  Most 
commonly, scientists examine the cells by microscopy to ensure they appear undifferentiated.  
By looking at the chromosomes of the cell under a microscope, it can also be determined if the 
cell has gone under any obvious genetic mutations. In other assays, the scientists analyze the 
genetic code of the cells to look for mutations, or analyze the types of transcription factors 
present. Transcription factors inside cells help regulate genes that turn on and off cell 
differentiation. Two important transcription factors that keep a cell in an undifferentiated state 
are NANOG and OCT4, both of which scientists look for when performing biochemical 
characterization.  
While embryonic stem cells show the most medical potential, they also have 
disadvantages to their use as well. Since the cells have not differentiated, they are simply a blank 
slate. They require complex chemical cues to change into the specific cell that is required for a 
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specific disease treatment. The cells also have a tendency to be rejected by the host immune 
system as invading cells. And ethically, their use produces strong debate on the ethical 
implications of life at conception. 
 
Induced Pluripotent Stem Cells 
Based on concerns with using ES cell research, scientists sought potential replacements 
for obtaining pluripotent stem cells without using a blastocyst. A breakthrough was made in 
2006 when Takahashi and Yamanaka discovered a way to induce regular mouse skin cells called 
fibroblasts to become pluripotent (Takahashi and Yamanaka, 2006).  And one year later, the 
same lab achieved the same success for human fibroblast cells (Takahashi et al., 2007).  
Originally done with the use of viruses encoding four transcription factors (OCT3/4 SOX2, 
KLF4, and c-MYC), scientists used the viruses to infect skin fibroblast cells, and the factors 
helped de-differentiate the fibroblasts to a pluripotent-like state, called an induced pluripotent 
stem (iPS) cell (Brind’Amour 2009).  
While this was one of the greatest breakthroughs in stem cell biology of the past decade, 
it raised some questions. One of the genes used in this procedure, c-MYC, had been linked to 
cancer growth.  Indeed, when the iPS cells were added to early stage mouse embryos, the mice 
grew like normal mice, but were at a much more considerable risk of growing tumors. It was also 
a concern that a retrovirus was being used to introduce the genes into the fibroblast, as 
retroviruses integrate at random positions in the host genome. But, both of these concerns have 
been now been pushed to a backburner, as further research showed that using only the NANOG 
and LIN28 genes in place of the c-MYC and KLF4 genes reduced the risk of tumor growth in the 
recipient of the iPS cells (Kim et al., 2008), and scientists could avoid using viruses altogether 
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and simply deliver the transcription factors themselves or use non-integrating plasmids (Yu et 
al., 2009).   
One key remaining debate point with iPS cells is their potency.  Some scientists claim 
iPS cells are as potent as ES cells, while others argue that iPS cells grow more slowly and have 
DNA mutations (Dolgin, 2010; Gore et al., 2011).  More research will be required to resolve this 
issue before using them for therapy. 
 
 
Parthenogenetic ES Cells 
Another method under intensive study to produce viable stem cells is parthenogenesis. 
Parthenogenesis is a process by which an unfertilized egg retains two sets of chromosomes and 
beings to develop as if it were a normal fertilized egg.  A few species of insects and reptiles that 
naturally undergo this form of replication, but it is not commonplace in mammals. Indeed, when 
parthenogenesis was attempted with mammals the embryos died within days of fertilization. 
Continuing with the research, it was found that the embryos of monkeys could be induced to live 
just long enough to become blastocysts and have their inner cell mass removed to derive ES cell 
lines (Mitalipov et al., 2001). Further research is being completed in the hopes that human eggs 
can be used to create parthenogenetic embryonic stem cells. Parthenogenetic embryonic stem 
cells would be genetically identical to the egg donor, so perhaps would be less likely to be 
rejected by that host.  Some scientists even envision someday using non-sexual reproduction to 
create a genetically homogenous cell line that would be accepted by all human hosts (Westphal 
2003).  Ultimately, deriving parthenogenetic ES cells still requires the use of an embryo, even if 
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the embryo has less potential than a fertilized one; therefore many individuals are against using 
them as well. 
 
Hematopoietic Stem Cells 
Adult stem cells are isolated from the adult tissues or from umbilical cord blood.  These 
cells do not destroy an embryo to obtain them.  Hematopoietic stem cells (HSCs) are the most 
researched type of stem cell in existence. Original research that led to the discovery of 
hematopoietic stem cells started in 1945 in Japan after studying individuals who survived the 
Hiroshima and Nagasaki bombs. Patients who had experienced radiation showed signs of 
damage to their hematopoietic system, and they seemed incapable of replenishing blood cells in 
their circular system. Through further experimentation in mice, it was observed that radiation 
exposure caused the same effects on hematopoiesis, and that adding fresh bone marrow post-
irradiation could alleviate the deficits (Lorenz et al., 1951; Nowell et al., 1956). This allowed 
scientists to propose the existence of blood forming cells inside the bone marrow. When cultures 
of the cells growing in the mice were transferred to other mice, it was observed that they 
continued to grow hematopoietic cells in the new host. This demonstrated that these cells have 
self-replicating properties.  
These HSCs proved to be very rare and hard to culture from the body, which remained a 
problem until the advent of cell sorting which allowed scientists to select for cells containing 
specific cell surface markers.  This process involved using fluorescent antibodies that would 
attach themselves onto different cell surface markers that represent HSCs, such as CD34. The 
attached antibodies made the cells glow, and the cell sorter could isolate the fluorescing cells.  
CD34+ cells turned out to have the same regenerative properties of HSCs.  The early methods of 
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identifying HSCs have not been expanded to include the following cells: Lin, CD34, CD38, 
CD43, CD45RO, CD45RA, CD59, CD90, CD109, CD117, CD133, CD166 and HLA DR 
(human) (Domen et al., 2006). Combinations of three to five of these markers produce almost 
pure samples of HSCs. 
 
Neuronal Stem Cells 
Research is also being done with other tissues to find adult stem cells. For years it was 
believed that cells of the nervous system could not replenish, but research in recent years has 
shown that this to be otherwise.  Neuronal stem cells (NSCs) were first identified and isolated in 
1989 from rat forebrains, and were shown to be capable of regenerating neuronal and glial cell 
types (Temple, 1989).  Adult NSCs were later isolated from the ependymal zones of rodent and 
human forebrains (Morshead et al., 1993).   
The main question with adult NSCs is their potency, and most of the applications for 
treating spinal cord injuries or neurodegenerative disorders use ES cells not NSCs.  For example, 
human ES cells have been injected into rats with spinal cord damage.  Three months after the 
injection, many of the rats could move again (Rebuilding the Nervous System…2009). This 
topic will be discussed in more detail in chapter-2.  Although adult NSCs appear to have some 
regenerative potential, it is not clear whether the potential is as great as ES cells (Rebuilding the 
Nervous System…2009).  
 
Mesenchymal Stem Cells 
Another adult stem cell is the mesenchymal stem cell (MSC). Discovered in 1976 by A.J. 
Friedenstein (Friedenstein, 1976), these stem cells are present in bone marrow and are easy to 
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isolate and culture. While mesenchymal stem cells are named after the mesenchyme, an 
embryonic connective tissue that will eventually differentiate into hematopoietic and connective 
tissue, these stem cells will not normally differentiate into hematopoietic cells. MSCs are also 
easy to isolate from umbilical cord tissue. Research also shows that these cells, when injected 
into the body are very efficient at finding their way to the bone marrow. This homing trait, and 
their broad mesodermal type differentiation, allows the use of MSCs for a wide range of 
therapeutic treatments (Nardi and Meirelles 2006).  
 
Epithelial Stem Cells 
Since stem cells are the body’s natural means to regenerate tissues, it would be expected 
that there would be stem cells located in the body’s first line of defense, the skin. Epithelial stem 
cells (ESCs) were first identified and isolated in 1981 from oral mucosa and skin (Bickenback, 
1981).  ESCs were also identified in transient amplifying cells in hair follicles (Jones and Watt, 
1993).  Adult stem cells are typically rare within their tissues, and it was hard to guess where in 
the skin ESCs were located. Since the skin grows in columns upward through the epidermal 
layer, it was hypothesized at first that the basal layer under the epidermis was entirely comprised 
of stem cells. However, radiation testing proved that only 2-7% of this layer was made of stem 
cells (Alonso and Fuchs 2003). Another study showed that 10-12% of the basal layer is 
comprised of stem cells. Further research is being done to identify specific protein markers on 
the cell surface (Cotsarelis et al., 1999; Alonso and Fuchs, 2003). 
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Cardiac Stem Cells 
Similar to the nervous system, the heart was also assumed unable to regenerate when 
damaged.  But like the nervous system, it was found to contain stem cells capable of replenishing 
heart muscle cells.  Cardiac stem cells have been characterized as c-kit cells (Beltrami et al., 
2003), and as Isl1+ cells (Laugwitz et al., 2005).  Inside the interstices of the heart, pockets of 
stem cells were discovered. These cells were harvested from rat hearts and used to test the ability 
of healing in their hearts. Researchers found that “70% of the damaged myocardium was 
reconstituted within 20 days”, and these researchers located the same kinds of cells in the human 
heart (Touchette, 2003). 
Many other types of adult stem cells have also been identified, and likely additional 
research will identify more.  None are as well characterized as HSCs or MSCs.  There is 
evidence to suggest adult intestinal stem cells (Barker et al., 2007), adult eye stem cells (Majo et 
al., 2008), adult renal stem cells (Oliver et al., 2002) also exist.  
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Chapter-2:  Stem Cell Applications 
Nick Van Sciver 
 
In the previous chapter, specific types of stem cells were introduced. This chapter will go 
further into the potential of these cells by discussing their ability to treat specific diseases in 
animal models or in human patients.  This discussion of how stem cells are used, and their 
benefits to society, strongly factors into the ethical discussions in later chapters on whether these 
cells should be used even when an embryo is be destroyed. 
 
An Introduction and General Stem Cell Applications 
  In 1998, the first human embryonic stem cell was isolated, marking the start of the huge 
rush to use this powerful pluripotent cell to produce cures (Thompson et al., 1998).  A report 
published in 2007 (Flanagan, 2007) examined the progress of stem cell research and concluded 
that the field has been accelerating quickly.  For example, although it is still in clinical trials, the 
company Tegion has a devised a method of creating a new bladder by incorporating a mixture of 
cells including bladder progenitor cells, smooth muscle cells, and urothelial cells, onto a physical 
scaffold that acts as a blueprint to allow the cells to form a bladder (Flanagan, 2007). In another 
case for the progression of stem research, the University of Pittsburgh has identified progenitor 
adult stem cells responsible for the regeneration of bone, muscle, and cardiac tissue. From the 
field of embryonic stem cell research, Advanced Cell Technologies, a biotech company formerly 
based in Worcester, MA has entered clinical trials treat forms of blindness with ES cells, and is 
one of the leading hESC companies in the world.  Another company, Geron Pharmaceuticals, 
initially entered clinical trials to use hES cells to treat spinal cord injuries, but stopped the trials 
in 2011 when they ran out of money (Baker, 2011).    
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Not only are universities and federal organizations interested in the potential of stem cell 
research, large pharmaceutical companies have been spending millions of dollars to harness their 
capability.  In 2010, the pharmaceutical giant Roche provided $20 million to Harvard University 
and its teaching hospitals to screen cell lines for any prospective treatments.  GE Healthcare, 
Pfizer, and GSK have all begun initiatives to look at the potential of stem cells. However, some 
companies remain skeptical of this new field due to the many long unfulfilled promises made 
(Baker, 2010).  Below is a realistic assessment of the use of stem cells of various types to treat 
four example diseases: leukemia, diabetes, spinal cord injuries, and ocular injuries. 
 
Hematopoietic Stem Cell Treatments 
           Hematopoietic stem cells (HSCs) are located in the blood, bone marrow, and umbilical 
cord blood. This type of stem cell has been the most extensively studied type of stem cell, and 
has been in use for decades to treat blood cancers leukemia and lymphoma.  The reason HSCs 
have been so thoroughly investigated is due to several advantages inherent in these cells: their 
relative abundance in bone marrow, their classification as adult stem cells which negates the 
ethical issues of ES cells, and the cells seem to be more potent than just able to make other blood 
cells.  The signature use of HSCs is to use bone marrow (their traditional source) transplants to 
treat leukemia (Thomas et al., 1957).  Less traditionally, HSCs have been used to treat severe 
combined immunodeficiency (SCID) disorders in which a patient has a non-functional immune 
system, or to treat heart tissue after myocardial infractions (Lunde et al., 2006). There are also 
commercial applications with HSCs, with companies like Viacord storing umbilical cord blood 
which is rich in HSCs for families to potentially save a life (Viacord, 2002).  With umbilical cord 
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HSCs, there are 80 treatable diseases, ranging from cancers to metabolic disorders (Viacord, 
2002). 
The traditional source of HSCs is bone marrow, but in 2002 scientists revealed that HSCs 
could also be found in the peripheral blood if the donor was treated with hormones to stimulate 
the movement of HSCs from the marrow (Verfaillie, 2002).  Peripheral blood has now become 
the most common source for HSCs due to its ease of isolation compared to bone marrow.  
However, cord blood HSCs were found to engraft better than marrow or peripheral HSCs. 
           As early as 2000, HSCs were used to treat severe combined immunodeficiency disease 
(SCID) in a fashion similar to treating leukemia (Cavazzana-Calvo et al., 2000). In this trial, two 
patients with SCID X1, the X- linked genetic version of the condition referred to as “bubble boy” 
in which the patient are missing the gene for gamma-C T-cell receptor that is necessary for 
immune system development. Usually SCID is treated by a bone marrow transplant from a 
compatible donor, but this allogenic procedure used the patient’s own bone marrow treated by 
gene therapy with the gamma-C gene responsible for their condition.  After harvesting bone 
marrow from a patient and adding the gamma-C transgene that would allow normal immune 
development, the bone marrow was reinserted into the same patient. Fifteen days after the 
procedure, the gamma-C transgene was present in the blood. Thirty days after the procedure, T-
lymphocytes had risen in number in the blood. As a result of this gene therapy HSC treatment, 
both patients’ chronic SCID symptoms subsided, and they were able to live at home (Cavazzana-
Calvo et al., 2000). While this trial showed great promise for HSC gene therapy in human 
patients, the trial pool of two patients was incredibly small. A few years later, gene therapy trials 
like this one seriously foundered when a patient died during the therapy due to a massive 
immune response to the virus used to deliver the gene (Stolberg, 1999). 
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HSCs surprisingly appear to be capable of curing more than just blood diseases. Heart 
attacks can kill heart tissue if the blood flow is cut off for an extended duration, and this can lead 
to further health complications (Orlic et al., 2001).  In 2001, BM cells were injected into mice 
that with an infracted heart. Nine days post implantation, the investigators found that 68% of the 
infracted region was occupied by expanding myocytes and vascular structures (Orlic et al, 2001). 
This basic repair happened in about 40% of the mice they operated on, while not perfect, shows 
the potential of HSCs to expand into other areas of regeneration. 
 
Stem Cell Treatment of Diabetes 
  One of the most widespread and debilitating diseases facing America is diabetes. With 
the prevalence of sugary foods and a population that is increasingly obese, the occurrence of 
diabetes has been increasing at an alarming rate. It is estimated that a staggering 25.8 million 
people in the US has either type-I or type-II diabetes.  Among people older than 65, 10.9 million 
or 25.6% of that population category have diabetes (NDIC, 2011).  Type-I diabetes results from 
the lack of production of insulin by the pancreas due to an autoimmune reaction.  Type-II results 
from a patient’s inability to respond to the insulin that is produced.  The typical treatment for 
Type-I is insulin injections (to replace the insulin not produced by the patient), but it is hard to 
maintain a precise normoglycemia using injections.  Diabetes has dire costs associated with it.  It 
is estimated to drain over $174 billion dollars annually from the economy in both direct and 
indirect costs to the patient. Of that amount, $116 billion dollars of that amount spent on direct 
patient costs, like medicine and healthcare. Another S58 billion dollars of this amount spent on 
indirect costs, such as work loss and premature mortality (NDIC, 2011). These statistics alone 
show that diabetes is a major health issue facing the United States.  
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One avenue that researchers are considering to cure diabetes is using stem cells to regrow 
pancreatic tissue capable of producing insulin.  One important finding is that of all the stem cell 
types, only ES cells are capable of replicating to high enough cell numbers to treat a patient 
(Kroon et al., 2008).  In 2008, investigators tested the ability of human ES cells to treat a diabetic 
mouse model.  To ensure that the human ES cells were differentiating into pancreatic cells 
secreting insulin, they removed the endogenous mouse pancreas (Kroon et al., 2008). The 
technique involved injecting a cellular toxin that destroyed the mouse pancreas due to its entry 
though a highly expressed cellular membrane protein on mouse cells but lacking in human 
pancreas cells. This creates a disease model similar to diabetes. After destroying the mouse 
pancreatic cells, the serum glucose increased like in diabetes. When the investigators implanted 
the human ES cells they found that the glucose in the blood fell to normal levels.  When they 
removed the graft, the glucose levels rose again.  The developing cells were glucose responsive 
and had similar properties to that of human pancreatic islet cells just after thirty days after the 
implant (Kroon et al., 2008). They found that 92% of the treated mice, an overwhelming 
majority, were able to generate enough insulin to protect against hyperglycemia. After further 
examination, the investigators found that the human ES cells had differentiated into endocrine 
cells that functioned much like normal pancreatic cells. This experiment was groundbreaking for 
showing that human ES cells have the ability to restore glycemia in a mouse diabetes model in 
vivo, showing that it could be possible with humans in the future. 
  In 2001, one of the earliest studies on human ES cells and diabetes showed that these 
cells had the ability to differentiate into insulin producing cells in vitro (Assady et al., 2001).  In 
this study, the scientists identified the rudimentary developmental pathway that human ES cells 
undergo to become pancreatic islet cells, a major step forward (Assady et al., 2001). However, 
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they were not able to determine whether the differentiated cells were glucose responsive, a 
necessary feature if they are to treat diabetes in vivo.  The study also noted that pancreatic stem 
cells already present in the pancreas could also differentiate into pancreatic islet cells. However, 
these precursor cells were very few in number, limiting their therapeutic application (Assady et 
al., 2001). 
  A few years later, in 2006, a different group studied the human ES cell differentiation 
process, further uncovering the mechanism of ES cell differentiation. This allowed the 
investigators to make insulin-producing cells more efficiently (D’Amour, 2006).  They were able 
to achieve impressive results of insulin-producing cells in amounts that surpassed the earlier 
studies, but it was still less efficient than with adult pancreatic islet cells. They were able to 
differentiate human ES cells into pancreatic endocrine cells at rate of 7% to 12% (D’Amour, 
2006). 
To date, while investigators have been successful in finding a method of creating 
pancreatic cells in vivo in mice, the mechanisms of these methods remains poorly understood. 
This has to be looked into further to prevent unforeseen medical consequences, and to further 
increase efficiency of the cells. In addition, treatments must be attempted using a patient’s own 
pancreatic cells, to allow an allogenic transplantation.  In the mouse studies, the mice were 
sacrificed at the end of the study and did not need to go on immune suppressors, while a diabetic 
patient would have to spend his life on them.  Foreign pancreatic grafts do not seem to survive in 
patients, even with immune suppressors taken.  And ES cells still pose the threat of teratomas if 
undifferentiated ES cells are implanted into a patient, so they may have to be differentiated in 
vitro and then implanted in order to provide for the patients safety.  
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In the future, perhaps induced pluripotent stem (iPS) cells could be used for treatment.  
These cells would be isolated from the skin fibroblast cells of a patient, and de-differentiated to 
make pluripotent cells, and then differentiated into insulin producing cells and injected.  
Hopefully since the cells would be the patient’s own cells, they would not be rejected.   However 
this would require the proper cocktail of transcription factors that do not cause mutagenesis or 
cancer, so would need to omit the original cMyc oncogene (Mayhew and Wells, 2010). On the 
bright side, progress made by this field shows that iPS cells can indeed form insulin-producing 
cells (Zhou et al., 2008), but there are still obstacles to overcome. 
 
Stem Cell Treatment of Spinal Cord Injuries 
           One of the holy grails in stem cell research has long been to repair spinal cord injuries. 
Every year, about 12,000 individuals suffer spinal cord injuries, and currently around 270,000 
people live with a spinal cord injury in the U.S. (NSCISC, 2012).  Not only do these injuries 
severely affect the quality of life for these individuals, it also severely drains the resources of the 
families and organizations that support them. With stem cell research advancing at the rate it is, 
there is the prospect of creating neurons that could replace the damaged neurons in the spine, 
allowing for signals to once again be transmitted across the body. The promise is tantalizingly 
close, with many encouraging studies successfully treating animal models.  
The types of stem cells used to treat spinal cord injuries in animal models varies from 
using human ES cells (MacDonald et al., 1999) to skin fibroblast cells (Vierbuchen et al., 2010). 
There has even been an initial human clinical trial for Geron Corporation , albeit one that was cut 
short due to lack of funds (Baker, 2011).  One of the first animal model tests observed the effects 
of human ES cell grafts in a rat model (Kerr et al., 2003).  The rats were able to recover some 
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motor function, while their control group counterparts did not.  However, their technique of 
adding embryoid-derived bodies differentiated from the ES cells was inefficient, as shown by the 
partial recovery of the rats. Furthermore, even the cells that fully differentiated did not fully bind 
to muscle synapses (Kerr et al., 2003). 
One of the most promising recent studies showed that using iPS cells derived from 
fibroblasts were able to be converted into neurons (Vierbuchen et al., 2010).  Using transcription 
factors Ascl1, Brn2 and Myt1l, scientists were able to create neurons in mice from both 
embryonic and post-natal fibroblasts (Vierbuchen, 2010). Not only did they become neuronal 
cells, but they were able to form synapses and could integrate themselves into pre-existing 
formations, a trait that is crucial for improving symptoms.  A huge improvement from previous 
studies was that the rate of differentiation was much more efficient, especially when considering 
tests done a decade ago.  As mentioned in the previous disease section, the use of iPS cells has 
potential advantages since they should not induce an immune response (Mayhew and Wells, 
2010). With the publishing of this study, the goal of regenerating spinal injuries seems almost 
reachable.  
           The transition from animal studies to human clinical trials has been hard due to the 
combination of the high cost of the clinical trial process and harsh economic times. Geron 
Pharmaceuticals was in phase-I of clinical trials starting in 2009, using human ES cells to treat 
patients for spinal cord injuries (New York Times, 2009).  But after two years, Geron ended the 
trial, citing financial concerns, not for a lack of promise (Akst, 2011). A leading scientist 
commented that “I think that other companies will pick up where Geron left off, but it may take 
them awhile” (Akst, 2011).  One commenter on the article noted this story had a silver lining, the 
simple fact that since human ES cells had begun clinical trials shows how far the field has 
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progressed towards a cure. 
 
Stem Cell Treatment of Ocular Diseases 
One promising area of stem cell research has been the examining diseases that affect 
eyesight. One of the leaders in this field against ocular afflictions is the biotech company 
Advanced Cell Technology (ACT), that was formerly based in Worcester, MA, and is now based 
in California and Marlborough.  After Geron Corporation capitulated in the ES cell field, ACT 
was the only company still running a clinical trial using human ES cells. ACT’s research focused 
on two diseases, Stargardt’s disease and macular degeneration. The former disease is genetic in 
nature, while the latter is due to the loss of photoreceptors with age.  The implant site was not 
random, there are several advantages to experimenting with hESCs in the eye. The foremost 
advantage is that the eye is a highly visible external organ, allowing for any dangers to be spotted 
in advance (Waters, 2012). A procedure done internally would not be as transparent. One other 
major advantage is the eye has no immune system presence, allowing for procedures like ACT’s 
to be done without the specter of graft rejection by an immune response (Waters, 2012). One 
major improvement in the process developed by ACT is the ability to detect a single 
undifferentiated cell out of a million differentiated eye cells. Teratomas, a form of cancer, could 
form if any undifferentiated cells were implanted. The therapy that ACT has been doing requires 
only 50,000 cells, making this cancer threat very unlikely (Waters, 2012).  So far, the patients 
who have been treated in the phase-I clinical trials are under watch in case of this cancer 
occurrence, and otherwise have experienced a rousing recovery. 
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Chapter-2 Conclusions 
The field of regenerative medicine, while still nascent for ES cells and for all types of 
adult stem cells except for HSCs, has rapidly produced results in lab models that can be 
considered medical miracles. From hematopoietic stem cells to spinal cord injuries, the results 
coming from these studies have been nothing short of amazing. An example done in animal 
models with diabetes returned to normal function after being treated with human ES cells (Kroon 
et al., 2008) or with iPS cells (Vierbuchen et al., 2010).  Even with these numerous animal 
studies that display of the potency of stem cells, these methods still need to go through clinical 
trials to establish legitimacy and efficacy.  The clinical trials are the first line of defense to shield 
the public against dangerous or ineffective drugs, but the process is incredibly expensive to go 
through. There are currently only two clinical trials in progress using human ES cells run by the 
same company, Advanced Cell Technology, with another clinical trial ended at Geron 
Pharmaceuticals due to financial woes. The initial results of the ongoing blindness clinical trials 
of ACT have shown to be life changing for some of the patients enrolled in them. It could be 
easily argued that based on some of the studies cited in this chapter, several different fields, like 
the field of pancreatic regeneration for diabetes, are ready to move forward into clinical trials, 
provided that an organization can ante up the funds to do so. There is a silver lining for the HSCs 
already on the market, these cells are expanding their applications in medicine by being 
commercialized by companies like Viacord storing umbilical cords as a safeguard against 
diseases like leukemia and SCID. With the widespread progress on stem cell research done in the 
last decade, it will be exciting to see what advances come with the next decade. 
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Chapter-3: Stem Cell Ethics 
Brandon Alspach 
 
 
Throughout the course of history, science has always been under scrutiny by the public 
eye.  While it gifts us with many possibilities, technologies that save, lengthen, and overall 
improve the quality of life of human beings, often individuals ask whether it is necessary.  
Science has provided us with the ability to isolate and grow different types of stem cells, and use 
them to treat a variety of diseases, but this controversial science is influenced and ultimately 
guided by ethics.  To many people, the harvesting of embryonic stem (ES) cells from embryos 
raises ethical questions of ending a possible life.  People debate on when life begins, and at what 
point does cell growth determine a person with the same rights as a living being.  Can the 
possible medical benefits of ES stem cells outweigh the value of the eventual person the 
blastocyst might have produced?  Throughout this chapter we will discuss the ethical 
implications of using stem cells, and whether we should use them.   
 
Introduction to Stem Cell Ethics 
Some scientists have argued that many diseases like Parkinson’s or type-I diabetes could 
become problems of the past. Cell regenerations through stem cells could help paralyzed 
individuals walk again, or Alzheimer’s victims reason again. As discussed in Chapters-1 and -2, 
the process by which we obtain ES cells destroys an embryo. Often times, when referring to stem 
cells as unethical, the arguments merge into a discussion of whether abortions are ethical.  ES 
cells however are not extracted from a womb of a woman. The blastocysts used to obtain stem 
cells arrive from an IVF clinic, created originally with the intention of helping infertile couples 
have a child. This process requires the creation of multiple fertilized embryos, as not all embryos 
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result in pregnancy. When the couple no longer need the embryos, they are either destroyed or 
donated for stem cell research. Since they are not harvested from a human womb, and no money 
is paid to the donors of the eggs and sperm, the process is compliant with President Obama’s 
current U.S. policies (discussed in Chapter-4).  So the debate focuses on whether a 5-day old 
blastocyst has the same rights to life as a living being.   
Many look to religion for answers to this important question, and it has played a large 
role in the debate.  Does life begin at conception?  At implantation into the uterine wall?  At day 
40?  At birth?  Although various religions can provide opinions on this key question, we cannot 
forget that the religions were founded at times far before stem cell technology existed, so in 
some cases they cannot directly address the question of a 5-day old embryo.  Others falsely 
believe that working with ES cells directly involves human cloning, or other controversial issues 
such as genetic discrimination and ownership laws. The true issue with stem cell research lies in 
deciding when does the combination of an ovum and sperm create a human life worthy of 
protection and given a chance to live and develop as its own being. 
 
Religious Views and Stem Cells 
Religion currently creates most of the opponent views of stem cell research. Roughly 
85% of the 6.8 billion people on earth call themselves religious.  The five major religions are 
Christianity, Islam, Judaism, Hinduism, and Buddhist (Griffin, 2010). 
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Figure 3.1: Diagram of Various World 
Religions by Percentage in 2007.  (World 
Religions 2008) 
 
 
 
 
 
 As of 2007, roughly one out of three people on earth are Christians (33.32%), and 
roughly one out of five people are Muslims (21.01%), leaving only a third of the world divided 
into other groups such as Hindus, Buddhists, non-religious, and atheists. With religious people  
seated firmly as majority this strongly affects most people’s views on stem cells (List of 
Religious Populations, 2012). 
 
Christianity and Stem Cells 
Christianity comprises the world’s largest religion, with around 2.3 billion followers 
worldwide.  Divided into three broad denominations, Roman Catholic, Eastern Orthodox, and 
Protestant, most Christians find themselves disagreeing on the subject of stem cell research. 
Roman Catholics, Eastern Orthodoxy, and Southern Baptist Protestants, teach the belief that life 
begins at conception (Kohsl, 2008).  To them, once a sperm cell and ovum join, a new life is 
created with rights to life. Since the genetic code of this new organism is unique to only itself, 
and it will retain this code until the day it dies, some argue that this is the defining moment when 
life begins. Since the process of obtaining ES cells requires the destruction of a five day old 
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embryo, the process is considered murder by these individuals. The Catholic Popes are among 
the most outspoken on this topic, and have been quoted several times specifically addressing the 
stem cell debate and against ES cell research (American Catholic Organization, 2006; Pope John 
Paul II, 2001). While Roman Catholics do not support the research or use of ES cells, they have 
a different view about adult stem cells and support their use and research (Pope Benedict XVI, 
2008). If less than a third of the world believes in life at conception, do we allow this minority to 
rule over the majority? A better question to ask ourselves, do we allow a religion to determine 
the outcome of what essentially is a human issue?  Many religions were founded as an 
explanation of what happens in the natural world around us, before common knowledge of 
science (in this case biology) existed. 
But this negative view on ES cell research is not the view of every Christian. Members of 
the Anglican-Episcopal church, a denomination of Protestantism, believe that an embryo does 
not become a human life until around fourteen days after conception, when the precursor to the 
spinal cord is formed (Faithful Progressive, 2005). Similarly, Presbyterians and members of the 
United Methodist Church believe that human embryonic stem cell research is acceptable, so long 
as the embryos are the remains of infertility treatments that women chose not to continue. To 
make the broad statement that one is Christian and therefore does not approve of embryonic stem 
cells is an uninformed statement. 
 
Islam and Judaism and Stem Cells 
The world’s second largest religion, Islam, takes a much different approach to stem cell 
research than Christianity. To them, while an embryo contains the potential to become a human, 
it is not quite yet a human. The embryo is incapable of self-sustained life, and if removed from 
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the womb, dies, so many believe in Islam that an IVF embryo outside the womb can be used for 
research (Siddiqi, 2002).  However, it is still important to treat any human embryo with respect, 
so the research must be done with the intent of benefiting mankind.   
To members of the Jewish faith, a similar belief is held. Here, it is generally believed that 
life occurs about forty days after conception (Dorff, 2001).  To Christians, the act of “playing 
God” is forbidden, as it is seen as usurping God.  However, Judaism teaches that it is acceptable 
to “play God” as long as it is done within the bounds of His laws. To Jews it is acceptable to 
support and use medical technologies that heal and preserve human life (Jakobovits, 2006). 
Manipulating a 5-day old embryo to save lives in Judaism is somewhat similar to manipulating 
tissues and organs. 
 
Hinduism and Buddhism 
While Judaism, Christianity, and Islam all developed as major religions in the same 
region of the world, the world’s other two major religions developed further east. Hinduism and 
Buddhism developed in the Indian subcontinent, and spread to become the dominant religions in 
most eastern Asian countries, as such their views are fairly similar to each other.  Hindus believe 
in a reincarnation system, in which lowest forms of conscious beings reincarnate as higher 
conscious beings as they die, eventually to become human, the highest conscious being. As such, 
to Hindus, human life is sacred, as it is the only life form that has the ability to reincarnate for the 
last time and find peace with their gods (Bahnot, 2008). However to most Hindus, the cell mass 
that makes up a blastocyst is not yet a human. As such they share a view similar to Judaism, if 
this technology can be used to heal humans, is it not a good one? Not all share this view 
however, since humanity is the last track to nirvana and it should be cherished.  
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Buddhism is more split when it comes to the ethics of ES cell research. His Holiness the 
Dali Lama has stated that it takes more than a fertilized egg to make a human being. Indeed he 
believes that the qualifying factor that makes up a human being is conscious thought (Dalai 
Lama, 2002). Along the lines of Hinduism, some Buddhists believe that an embryo contains the 
“karmic identity” of the individual that it once recently was, and therefore has rights to life and 
protection (Keown, 2004). As for the other religions, it is generally agreed in Buddhism that use 
of adult stem cells is permissible, but the use of ES cells is still under great debate (Holmes, 
2004). 
 
The Moral “Slippery Slope” 
To others throughout the world, murder of embryos is not the main problem of ES cells, 
but the creation of more humans. Many believe that from therapeutic stem cell work (which 
involves no cloning), logically the next step is therapeutic cloning and eventually human 
reproductive cloning.  In the slippery slope theory, individuals see a non-stop progression from 
one to the next (ES cells, therapeutic cloning, reproductive cloning), without stoppage.  If 
scientists could create a new liver for a person, what would stop them from just creating that 
person genetically as a whole?  Many fear the possibilities of what human “cloning” holds, while 
not having a full understanding between the differences of therapeutic cloning and reproductive 
cloning. The process of therapeutic cloning involves taking the nucleus from a skin cell and 
injecting it into an enucleated egg and growing it in vitro to create an IVF embryo, from which 
patient-specific ES cell lines can be derived.  These ES cells would be genetically identical to the 
donor of the skin cell, and this process has been achieved in animals (Byrne et al., 2007), but not 
in humans (early claims in Korea were later retracted for data fabrication).  Reproductive cloning 
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involves a similar process, except the blastocyst is implanted into the uterus of a foster mother 
for the purpose of pregnancy.  This process however is outlawed in all countries that have 
bothered to make any laws governing stem cell use, and will be discussed further in Chapter-4.  
If a person employed science to create a clone of themselves, then who owns the clone?  If 
someone’s own money went into developing a clone, does that make that human life their 
commodity?  Many fear how far science will go to push the boundaries, and their valid fears of 
reproductive cloning have clouded their opinions on ES cell use and on therapeutic cloning.  
 
 
Induced Pluripotent Stem Cell Ethics 
Research into stem cells is not limited to embryonic stem cells. The current hotbed of talk 
in stem cell research is all about induced pluripotent stem (iPS) cells. These stem cells started as 
normal skin fibroblasts, and had transcription factors introduced into them to turn on specific 
genes to induce pluripotency (Takahishi et al., 2007).  These cells show great promise as some 
scientists claim they are as potent as ES cells, but they destroy no embryos.  Interestingly, to 
some they raise the same number of questions as ES cells.  
Originally the protocol to induce pluripotency used 4 genes, of which one c-Myc an 
oncogene was later found to sometimes induce tumors at the injection site.  But this problem was 
later resolved as further research discovered how to force the cells to a stem cell state without 
including the c-Myc component (Nakagawa et al., 2008; Deem 2009).  These cells are still 
undergoing much research and their true potency is under debate.  Some ague the cells are 
pluripotent, while others argue they are less potent than ES cells. Some even argue that iPS cells 
are totipotent.  If iPS cells are ever shown to be totipotent, they could make entire organisms if 
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they are implanted into a uterus.  In that case iPS cells would have the same ethical concerns as 
ES cells, but this has not been shown.  While totipotency is only a plausible scenario at the 
moment, if it is discovered that these cells can become totipotent, it removes all advantages they 
have over embryonic stem cells (Brind'Amour, 2009). 
 
Chapter-3 Conclusions 
Today as science pushes our knowledge of our physical world, do we allow such 
antiquated and outdated systems like religion to dominate?  I personally disagree with the beliefs 
of Roman Catholics, Easter Orthodoxy, and Southern Baptists, that life begins at conception. 
However, I do believe that after later in pregnancy life begins. Even if fertilization creates a new 
genetic code, the new embryo is unable to sustain life on its own without implantation. Before 
we rise up and call the harvesting of embryos for research murder, take a look around at the 
world at various diseases, and if we could help alleviate some of them using stem cells, shouldn’t 
we?  If embryonic stem cells, adult stem cells, and induced pluripotent stem cells can be used to 
heal people and help alleviate suffering, I see no problem with using any of them.   
However, I do believe in some restrictions on stem cell research.  I believe there is a limit 
to how these embryos should be obtained, only by surplus or research purposed IVF embryos 
with unpaid donor consent.  Once someone begins to pay another for an embryo, the same 
“slippery slope” mentioned before comes into my mind, as egg donors might be coerced into 
undergoing a risky medical procedure of donation merely because they need the donor money. 
The thought of creating a commodity out of what could become a human life sickens me. Money 
is the driving force behind most of what happens in our world, and there is no need to make a 
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business out of life. Furthermore, I also believe that stem cell research should have a focus, with 
only therapeutic applications in mind.  
While some cry murder on the loss of a blastocyst, to others these tiny balls of cells can 
be seen as a gift. While many say give that embryo a chance to make its own life, ultimately we 
will never know what life it might have, the best or worst.  Ultimately if we can ease the pain of 
living, then this should be further researched. After all, only through life do we, the living, suffer. 
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Chapter-4:  Stem Cell Legalities 
Nicholas Van Sciver 
 
Since the discovery of stem cells in 1981 and the emergence of regenerative medicine, 
legalities for this field have become complex. Specifically, it is the controversial nature of 
embryonic stem (ES) cell research, where an embryo’s cells are harvested in order to conduct 
research. Because of this method, which can be seen as taking the life of a person, individuals 
with pro-life views often oppose embryonic stem cell research. In more conservative countries, 
this has led to a complete ban on ES research.  In the United States, the laws governing stem cell 
research often depend on the political administration in power at the time, and the policies vary 
from state to state. Over the course of three presidents, the United States has had widely differing 
stem cell policies, and the next administration may have an entirely different policy.  In addition 
to the whims of each Commander in Chief, a few states have taken matters into their own hands, 
approving bonds to fund their own stem cell institutes.  Some states have more lenient laws, such 
as New Jersey and California, which allow the state funding of ES cell research, while other 
states are prohibitive by comparison.  It should be noted that every U.S. president and state has 
supported adult stem cell research, but each has had varying views on ES cell research.  In 
addition, the laws on stem cells vary from country to country. In countries such as Sweden, the 
Netherlands, Belgium and China, ES cell research is strongly supported, while other countries 
like Germany, Poland, Estonia, Italy and Cyprus, have major regulations that block scientists 
from accomplishing their work. Regardless of the location, stem cell research is a hotbed of 
controversy not likely to anytime soon.  The purpose of this chapter is to discuss laws that 
regulate this controversial technology in the U.S., on both the federal and state levels, as well as 
abroad, focusing on how politics affects science. 
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The Clinton Era Embryo and Stem Cell Policies 
The Clinton era (1993-2001), near the beginning of human embryo research, had several 
different positions on ES cell research over the course of the administration. During his first year 
of office in 1993, the President lifted a moratorium instated previously by George H.W. Bush 
(Clinton, 1994).  Soon after this action took place, the President received thousands of letters in 
opposition of his move, so in a statement on December 2nd, 1994, the Clinton Administration 
stated its opposition against the destruction of human embryos to further research, and ordered 
the NIH to withhold funding from human embryo initiatives (Clinton, 1994).  In addition, in 
1996, congress passed the Dickey-Wicker Amendment, banning federal funding for embryo 
research (Genetics and Public Policy Center, 2011).  Thus, during most of the Clinton 
Administration, human ES cell research was banned (Green, 1995).   
However, during the twilight of the Clinton Administration, the National Institute of 
Health once again recommended that research on ES cells be federally funded.  The Clinton 
Administration this time agreed with this recommendation, and allowed the research to be 
funded (Clinton, 2004).  After his presidency, the former president stated in his autobiography 
(Clinton, 2004) it was the promise that ES research could help cure diabetes that made him 
change his position; several of his close friends had the disease and he realized that the moral 
controversy was not as important as human health. 
 
The Bush Era Embryo and Stem Cell Policies 
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Because deriving ES cells usually destroys an embryo, which some politicians view as “a 
living person”, there are politicians opposed to ES cell research and attempt to limit it by 
banning federal funding.  The Bush Administration (2001-2009) enacted laws in line with this 
mode of thinking.  Based on his own recommendation, within the first month of George W. 
Bush’s 2001 inauguration, federal funding was cut for embryo research (Bush, 2001; Bash, 
2006).  This ban went against the NIH recommendation to fund such research only a few months 
before.  On August 9th, 2001, Bush declared that scientists could only access previously existing 
ES cell lines, no new ES cell lines could be derived with federal funding.  In addition to those 
limitations, previous ES cell lines could only be used if they met several requirements: the 
embryos under consideration were derived for reproductive purposes and not needed anymore, 
informed consent must have been received from the donor, and no financial gain resulted from 
this venture.  IVF embryos could not be created solely for research purposes.   
Although adult stem cells destroy no embryos, they are harder to grow, are harder to 
isolate, and are not as potent.  In other words, adult stem cells can differentiate into only a few 
cell types.  As a result of the limitations imposed by the Bush Administration, only a few dozen 
ES cell lines were qualified for federal funding.  It was later found that several of these lines 
were unfit for research due to DNA mutations (Dolgin, 2010), leaving only a handful of ES cell 
lines available to American researchers.  Although the data produced from these embryonic stem 
cell lines showed they were not ideal for medical research, new lines could not be derived using 
federal funding.   
In 2006, President Bush used the first veto of his presidency to reject an ES cell research 
bill that would have lifted his previous restrictions allowing IVF embryos for research.  This veto 
was enacted in spite of its approval in Congress, passing 235 to 193 with bipartisan support from 
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both Democrats and Republicans. Not only did Bush veto something supported by both parties, 
at that time around sixty percent of Americans approved of ES cell research. This rejection of the 
bill was also a rejection of the will of the majority of people. Scientists after Bush left office said 
that the field of stem cell research lagged for eight years under his leadership. Many scientists 
believe that this 2001 federal ban on embryo research hindered the U.S. position in this field of 
science (Holden and Vogel, 2002; Rowley, 2002; Ford, 2006).   
 
The Obama Era Embryo and Stem Cell Policies 
One of the first things that President Obama did when he first took office in 2009 was 
overturn the 2001 ban set in place by the Bush Administration on federal funding for ES cell 
research (Borenstein, 2009; Hayden, 2009).  Obama, like Bush, set about his agenda very 
quickly. A month after Obama’s election, the newly designated Commander in Chief repealed 
the laws that declared that only certain cell lines could be used for federal funding.  The number 
of ES cell lines that researchers could now use increased from a few dozen to several hundred. 
This allowed scientists to shift their focus from finding ES cell alternatives, to using federal 
funding to actually do research on finding cures.  Scientists during Obama’s announcement were 
enthusiastic, saying it was a chance for them to catch up on eight years of lost science.  Although 
Obama’s policy is more lenient than Bush’s, it still requires the embryos to be obtained from IVF 
clinics with donor consent, so embryos still cannot be made with federal funding solely for 
research purposes. 
One thing that has not changed under Obama is a general lack of support for reproductive 
cloning, the creation of genetically identical individuals by somatic cell nuclear transfer. His 
stance on reproductive cloning is that “We will ensure that our government does not ever open 
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the door to cloning for reproduction. It is dangerous, profoundly wrong, and has no place in our 
society, or any society” (AP, 2009). In addition to this limitation, the 1996 Dickey Wicker 
amendment banning some types of embryo research still remains, despite Obama’s removal of 
Bush’s main policies on ES cell research. This amendment was passed in 1996 during the 
Clinton administration (Genetics and Public Policy Center, 2011). Its purpose was to prevent the 
Department of Health and Human Service (which funds the NIH) to provide research money for 
investigations that have human embryos created for research purposes.  Fortunately, due to the 
bill’s age and a slew of legislation over the years passed, its ability to restrict funding has turned 
out to be limited.  
 
Individual U.S. State Stem Cell Initiatives 
During the Bush Administration’s ban on spending federal money for embryo research, 
several individual states and institutions took matters into their own hands to use state funds to 
support ES cell research.  Seeing that America was falling behind in a field with huge medical 
potential, several state governors and legislatures approved bonds to fund ES cell research and 
new facilities (Figure-1). While state funds provide a lifeline to beleaguered scientists in the 
field, state funding is not as extensive as federal funding. 
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Figure-1:  Various U.S. State Policies on Human Embryonic Stem Cell Research as 
of 2005.  Shown are states that encourage ES cell research (blue), restrict ES cell research 
(red), or have no policies (gray) as of 2005.  (Specht and Hurt, 2005) 
 
California 
The most definitive example of an individual state funding its own stem cell initiatives is 
California with its $3 billion dollar state bond to fund ES cell research (Karmali et al., 2010).  
Former governor Arnold Schwarznegger proposed this funding via a ballot known as Proposition 
71 that was eventually approved (Hayden, 2008). With the legislation passed, the state declared 
it would annually contribute $300 million towards research for the next ten years, mostly through 
California’s Institute for Regenerative Medicine (CIRM). The CIRM  has provided a total $1.4 
billion dollars towards dozens of organizations such as the UC system schools and Stanford 
University (California Institute…. 2011).  While much of this grant money has gone to 
academia, CIRM also has made investments in the biotechnology industry. There were three 
objectives to these grants:  First, to aid companies into getting their products into phase III 
human clinical trials. Secondly, to provide funding to foster development of the products and 
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thirdly, to establish a bridge between academia and industry that could improve stem cell 
expertise and knowledge.   
However, there are some issues with CIRM.  The board of CIRM is structured so that 
many of the members come from the same institutions funded by CIRM.  Many believe this to be 
a conflict of interest, and it even lead to one chairman resigning. Despite this flaw, the majority 
of the grant money in California has gone toward human ES cell research, while in other states 
this target was not a major destination for the grants.  
 
New Jersey 
After Bush declared his federal regulations on hESCs, the more liberal states began 
initiatives to fund unregulated ES cell line research. The first state that began this trend was New 
Jersey, which awarded $270 million to create the Stem Cell Institute of New Jersey (SCINJ) 
(McGreevey…2004). However, despite this initial promised foray into the field of ES research, 
investigations have slowed down in New Jersey as a half billion dollar initiative was turned 
down by the state voters who believed that the initiative was intended to provide for research, not 
just the construction of a new building  dedicated to ES research (Wadman 2008). In 2008, less 
than eight months after the ground breaking of the SCINJ’s main building, the state pulled back 
its funding, stating that the program needed to have a plan. As of 2012, the central headquarters 
located in New Brunswick had not been built, in spite of promises for the building’s 
completion.  However, satellite facilities have been constructed and functional in three locations 
in New Jersey, offering those that are interested in the field a chance to experiment. 
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Massachusetts 
There is a litany of reasons why Massachusetts is a world leading hub for biotechnology.  
The state is renowned for its powerhouse research institutes. Additionally, the state is home to 
dozens of influential and colleges like Harvard, MIT, BC, BU, Northeastern, and those are just 
the schools within the city limits of Boston.  The city’s resident teaching hospitals are the envy 
of other states, as they draw more federal grants than any other location.  And, Massachusetts is a 
bastion of liberal scientific policies, including those that allow ES stem cell research. However, 
Massachusetts was slow to start the race for stem cell research. Under former Governor Mitt 
Romney (2003-2007), the state’s support for ES cell research was hindered by his veto of any 
legislation proposing to fund such research.  The senate approved in 2005 passage of the Act 
Enhancing Regenerative Medicine in the Commonwealth (An Act….2005), which stated that 
hESC research’s potential made it worth studying, and therefore it should be a priority for the 
state to foster its growth.  But Romney vetoed this act.   
Romney’s policies resulted in the state’s inability to join California and New Jersey until 
January of 2007 when Deval Patrick took office and proposed legislation for a leviathan $1 
billion dollar research bill (Shelton, 2007; Life Science Bill….2008). This bill has further 
enhanced Massachusetts as not just a national, but global power in the life sciences, funding 
projects like the University of Massachusetts Medical School (Worcester) stem cell bank, which 
would store ES cell lines from around the world and allow information to be more easily 
accessed. While this bank went defunct in 2012, many other projects were still up and running.  
It also funded events like the BIO convention, in 2007 and 2012, that resulted in several stem 
cell companies relocating to the Greater Boston Area. 
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Misc. States 
During the Bush era, even some states with conservative governors supported stem cell 
research. In 2003, Ohio, under the leadership of Republican Bob Taft created at $500 million 
stimulus called the Third Frontier for his state, which included funds to support adult stem cell 
research.  The 2003 bill led to the creation of the Center for Stem Cell and Regenerative Science, 
using only ES cell lines approved by Bush or adult stem cell lines (Ertelt, 2005).  
Many states severely restricted or outright banned research on ES cells, including any 
funding with state money (see pink states in Figure-1).  These states included as examples, 
Arkansas, Arizona, Indiana, Iowa, Louisiana, Ohio, Oklahoma, Minnesota, Montana, Nebraska, 
New Hampshire, Maine, North Dakota, Pennsylvania, Rhode Island, South Dakota, Tennessee, 
and Utah.   
Were the actions of these individual states correct? From the author’s personal 
perspective, science should not be limited by politicians with no experience or insight in the 
field. Science should remain a politically-neutral topic, and banning of research should only be 
done with a panel of scientists and supporting experts on the topic in support. During the Bush 
administration, many feel that this was not the case. The NIH before Bush’s arrival to office 
recommended that ES cell research receive federal funding. The committee responsible for the 
recommendation was a broad mixture of scientists, clinicians, ethicists, lawyers, patients, and 
patent advocates who had spent years on the subject, and Bush ignored them. From a state’s 
perspective, where the money goes is the decision of its citizens. Under Bush, ES cell research 
was not outlawed, but its federal funding was tightly regulated. Some states have chosen to 
provide their own state funds to scientists, and so, have bypassed this funding restriction. As long 
as the constituents of the state vote for policies like that of California and Massachusetts, then 
 49 
there is nothing wrong with their actions because it is supported by the general public of those 
states. 
 
Other Countries Stem Cell Laws 
The United States is not the only land where stem cell research has produced a firestorm 
(Figure-2). On the other side of the pond, the European Union has yet to produce a united stance 
on the research; the EU bloc has produced policies that show the entire spectrum of responses to 
the controversial measure.  In fact, some of its member countries (Germany for example) are the 
only nations that outright ban ES cell research. While in others, such as Sweden, ES cell research 
is openly allowed. Other nations outside the Western realm of influence have also been involved 
with this controversial field.  In China, ES cell regulations are quite relaxed, even allowing for 
questionable practices to be put into action.  In Israel, this religious nation has been able to come 
to terms with the stem cell controversy after a fierce early debate. In a surprising twist, the Iran 
theocracy actually supports human ES cell research. The observation of these nation’s actions as 
they deal with the controversy is an opportunity for the United States to learn from these nation’s 
successes and failures. 
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Figure-2:  Diagram of Several Countries Embryonic Stem Cell Policies as of 2008.  
Shown are countries with permissive policies (green), intermediate policies (yellow), 
restrictive policies (brown), no policies (blue), or policies determined both federally and 
by each state (red).  (StemGem, 2008) 
 
Britain 
One of a group of European nations that conducts human ES cell research, the UK has 
long dealt with science of a controversial nature. The first test tube baby was born in Britain in 
1978 (Boyd, 2009), and not long after this monumental discovery British scientists sat down to 
discuss the ethics of using embryos in science. After two years of deliberation, it was decided 
that almost any research would be allowed, but with strong oversight. This was done by 
establishing a committee that would oversee any embryo being used for research in Britain. 
When ES cell research came of age, the system was already in place for it to be conducted 
ethically in this country. The organization behind this oversight is called the Human Fertilization 
and Embryology Authority (HFEA) (Rosenthal, 2004).  HFEA’s main function is to issue 
licenses both public and private to embryo researchers. While the HFEA model has attempted to 
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be emulated in several other countries, some people do not like the way it is run. The main 
complaint is that the committee board is full of people strongly in favor of ES cell research. But 
thanks to the HFEA’s structure, scientists quickly got to work on this new field with few 
obstacles. This favorable environment even led to some scientists emigrating from the US to the 
UK during the Bush era (Ford, 2006). 
 
China 
 In China, the government has taken a different stance on stem cell research. Since most 
Chinese do not practice a Judeo-Christian religion, the majority of the population does not take 
issue with ES cell research. This has resulted in much easier access to ES cell lines than in the 
United States.  The Chinese government and the private sector have both sponsored the research 
extensively. A new stem cell center in Shanghai recently sprang up with a price tag of $260 
million, complete with state-of-the-art capabilities. Researchers from Western countries agree; 
after visiting one of China’s new research centers, one scientist was “flabbergasted” at the 
advanced research the Chinese were performing (Barnes, 2006). Strong support from the 
government is not the only reason for China’s move to the forefront; due to the nation’s lax 
regulations on human drug therapies, many scientists are moving their experiments from the lab 
to the operating table faster.  One doctor has claimed to have performed over 600 procedures 
with stem cells that have seen improvements 70% of the time (Barnes, 2006). Many of his 
patients were from western countries, whose governments would never have allowed these 
unproven procedures to be performed so recklessly.  
In addition to these troubling rapid clinical procedures, there are academic honesty and 
plagiarism issues with the Chinese research itself (Murray, 2006).  Some peer reviewed Chinese 
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experiments have been slammed after being shown to result from blatant plagiarism. Some 
results are completely fabricated, but still make it into Chinese journals. The regulation of these 
charlatan papers have held China back from being respected as a scientific juggernaut. It is hard 
to take their scientific achievements seriously if these major issues are not dealt with thoroughly. 
 
Israel 
Israel is a powerhouse in ES cell research, despite the huge religious influence on the 
nation. While spilling blood for the sake of another human deserves capital punishment under 
Halacha, the Jewish law, ES cell research is allowed. The usual source of ES cells is from IVF 
embryos created in a petri dish, which do not fall under the Halacha since the embryo was 
created outside the human body.  A rabbi interviewed said “I can either throw them away, or I 
can use them for medical research" (Boyd, 2009).  Israel debated the legalities, and its citizens 
embraced a principle known as “pikuach nefesh”, which states that people must do all they can to 
save human life. This includes medical research like ES cell research. Pikuach nefesh is not only 
espoused by Judaism’s rabbis, but also by Muslim clerics, explaining why religious nations like 
Iran also tolerate hESC research. Since they had the option to either throw these surplus eggs 
away or use them, the decision for the Israelis was simple. They chose to use them to try to save 
lives in accordance to pikuach nefesh, as long as the stem cells are not used for profit.  This 
success has led Israel to publish more papers on stem cell research per capita than any other 
nation (Boyd, 2009).  They lead the world in liver regeneration, and the researchers at Hadassah 
University were the first to create brain cells via stem cells. Israeli scientists are also responsible 
for creating a stem cell pacemaker which has the potential to replace electronic pacemakers. 
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PROJECT CONCLUSIONS 
 
 
 
While the authors of this project have some moral qualms about working with what could 
be viewed as a potential human life, the use of these cells has a purpose. The point of working 
with ES cells is to treat to diseases that would not be curable otherwise.  Diseases like heart 
attacks, Parkinson’s disease, Alzheimer’s disease, or spinal cord injuries are mostly untreatable 
today.  Animal studies with stem cells have shown the potential to reverse such conditions, and if  
those treatments are also effective at clinical trials, it would change thousands of people’s lives 
for the better.   
In the U.S. under the Obama administration, human embryos for deriving ES cells must 
come from surplus IVF embryos provided with donor consent.  These embryos are destined to be 
discarded by the reproductive clinics that donate them, so from the authors standpoint, this 
represents a valid source of embryos. Like the view of the Jewish religion, pikuach nefesh, these 
IVF-derived embryos should be used to better the lives of others if they are going to be destroyed 
otherwise. This in the author’s eyes provides an acceptable compromise for those individuals 
who are pro-life.  We also agree with the current administration’s ban on financial compensation 
to donors.  Paying egg donors could lead to serious ethical issues, in the authors’ views, 
analogous to paying organ donors, a practice that is illegal in the US, and could put undue 
pressure on the poor to provide eggs and undergo a potentially risky medical procedure.  
With respect to which stem cells should be used to treat a specific disease, the authors 
believe that whichever type of cell works best for that disease should be used, even if this 
involves ES cells.  Although adult stem cells (ASCs) have few ethical issues, they are hard to 
grow in large enough quantities to be used in therapies.  ES cells while ethically controversial 
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grow well, and are very adept at differentiation.  However, these cells can sometimes create 
teratomas and immune rejection, so patients should be monitored for these effects.  iPS cells if 
derived from a patient’s skin fibroblast cell, do not carry the risk of immune rejection if used in 
that same patient, but cocktail of factors used to make iPS stem cells can be oncogenic, so we 
recommend the use of the recent cocktails that omit the use of the c-Myc oncogene component. 
Each stem cell type has its advantages and disadvantages. The authors believe that an 
investigator should take a practical approach to treating each patient. 
With respect to stem cell laws, the authors believe that Britain and Israel are the most 
pragmatic, as they both permit and fund ES stem cell research. The British were quick to break 
ground and establish ethical guidelines that streamlined the scientist’s ability to apply for 
funding, while keeping the process transparent and ethical. This approach, which uses an 
overseeing board to rapidly review and permit individual projects, should be adopted in the U.S. 
and would be a lot more stable than changing funding with every election cycle. It is also the 
authors’ beliefs that the Israeli’s pikuach nefesh of benefitting others has resulted in a more 
ethical system for that nation, particularly with regard to ES stem cells. We also support their 
belief that profits should not be derived from ES research, a philosophy can enable to a more 
responsible field of research not driven by profit incentives. There is no denying that the human 
clinical trials currently underway by Advanced Cell Technology (formerly of Worcester) using 
human ES cells to treat blindness are pathfinders for the field of regenerative medicine. Because 
of the intense moral beliefs that surround ES research, profiting from such research should be 
illegal, and the government’s primary role should be developing guidelines and ensuring 
adherence to these rules. 
 
